Cargando…

Proteomic Analysis Provides Insights Into the Therapeutic Effect of GU-BEN-FANG-XIAO Decoction on a Persistent Asthmatic Mouse Model

Gubenfangxiao decoction (GBFXD) is a traditional Chinese medicine based on a combination of Yu-Ping-Feng-San and Erchen decoctions. GBFXD has been widely used for decades in treating asthma at the Affiliated Hospital of Nanjing University of Chinese Medicine. Previously, GBFXD was found to reduce lu...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Li-wei, Xing, Qiong-qiong, Zhao, Xia, Tan, Min, Lu, Yuan, Dong, Ying-mei, Dai, Chen, Zhang, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514195/
https://www.ncbi.nlm.nih.gov/pubmed/31133848
http://dx.doi.org/10.3389/fphar.2019.00441
_version_ 1783417847206117376
author Liu, Li-wei
Xing, Qiong-qiong
Zhao, Xia
Tan, Min
Lu, Yuan
Dong, Ying-mei
Dai, Chen
Zhang, Yang
author_facet Liu, Li-wei
Xing, Qiong-qiong
Zhao, Xia
Tan, Min
Lu, Yuan
Dong, Ying-mei
Dai, Chen
Zhang, Yang
author_sort Liu, Li-wei
collection PubMed
description Gubenfangxiao decoction (GBFXD) is a traditional Chinese medicine based on a combination of Yu-Ping-Feng-San and Erchen decoctions. GBFXD has been widely used for decades in treating asthma at the Affiliated Hospital of Nanjing University of Chinese Medicine. Previously, GBFXD was found to reduce lung inflammation and airway remodeling; however, the underlying mechanism remains unknown. In this study, the effects of GBFXD on asthmatic mice were evaluated based on pathology and lung function; airway hyperresponsiveness (AHR) and pathology were compared among the two different mouse models utilized. Furthermore, the mechanism of action of GBFXD on asthmatic mice was analyzed using iTRAQ labeling technology combined with ingenuity pathway analysis (IPA). Modeling analysis of pre- and post-treatment proteins identified 75 differentially expressed proteins. These proteins were related to B-cell development, calcium-induced lymphocyte apoptosis, antigen presentation, and Th1 and Th2 activation pathways. Moreover, 68 differentially expressed proteins were identified in the GBFXD treatment group compared with the model group. Upstream regulatory factors predicted that interleukin (IL)-4 (necessary for inducing polarization of type 2 [M2] macrophages), cyclooxygenase, and prostaglandin E2 are significantly elevated in the model group. Based on IPA analysis, it was concluded that several pathways, including mitochondrial dysfunction and oxidative phosphorylation, are closely associated with the therapeutic effects of GBFXD in asthma. Moreover, the differential expression of several proteins, including the M2 markers, MRC1, ARG1, Retnla, Chil3, and CHIA, were validated by western blotting, confirming that GBFXD can reduce airway inflammation, which fits the pattern of an alternative M2 activation state, and attenuate AHR. Overall, our findings indicate that GBFXD significantly suppresses M2 macrophage polarization, providing further insights into the mechanism underlying the protective effects of GBFXD.
format Online
Article
Text
id pubmed-6514195
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-65141952019-05-27 Proteomic Analysis Provides Insights Into the Therapeutic Effect of GU-BEN-FANG-XIAO Decoction on a Persistent Asthmatic Mouse Model Liu, Li-wei Xing, Qiong-qiong Zhao, Xia Tan, Min Lu, Yuan Dong, Ying-mei Dai, Chen Zhang, Yang Front Pharmacol Pharmacology Gubenfangxiao decoction (GBFXD) is a traditional Chinese medicine based on a combination of Yu-Ping-Feng-San and Erchen decoctions. GBFXD has been widely used for decades in treating asthma at the Affiliated Hospital of Nanjing University of Chinese Medicine. Previously, GBFXD was found to reduce lung inflammation and airway remodeling; however, the underlying mechanism remains unknown. In this study, the effects of GBFXD on asthmatic mice were evaluated based on pathology and lung function; airway hyperresponsiveness (AHR) and pathology were compared among the two different mouse models utilized. Furthermore, the mechanism of action of GBFXD on asthmatic mice was analyzed using iTRAQ labeling technology combined with ingenuity pathway analysis (IPA). Modeling analysis of pre- and post-treatment proteins identified 75 differentially expressed proteins. These proteins were related to B-cell development, calcium-induced lymphocyte apoptosis, antigen presentation, and Th1 and Th2 activation pathways. Moreover, 68 differentially expressed proteins were identified in the GBFXD treatment group compared with the model group. Upstream regulatory factors predicted that interleukin (IL)-4 (necessary for inducing polarization of type 2 [M2] macrophages), cyclooxygenase, and prostaglandin E2 are significantly elevated in the model group. Based on IPA analysis, it was concluded that several pathways, including mitochondrial dysfunction and oxidative phosphorylation, are closely associated with the therapeutic effects of GBFXD in asthma. Moreover, the differential expression of several proteins, including the M2 markers, MRC1, ARG1, Retnla, Chil3, and CHIA, were validated by western blotting, confirming that GBFXD can reduce airway inflammation, which fits the pattern of an alternative M2 activation state, and attenuate AHR. Overall, our findings indicate that GBFXD significantly suppresses M2 macrophage polarization, providing further insights into the mechanism underlying the protective effects of GBFXD. Frontiers Media S.A. 2019-05-07 /pmc/articles/PMC6514195/ /pubmed/31133848 http://dx.doi.org/10.3389/fphar.2019.00441 Text en Copyright © 2019 Liu, Xing, Zhao, Tan, Lu, Dong, Dai and Zhang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Liu, Li-wei
Xing, Qiong-qiong
Zhao, Xia
Tan, Min
Lu, Yuan
Dong, Ying-mei
Dai, Chen
Zhang, Yang
Proteomic Analysis Provides Insights Into the Therapeutic Effect of GU-BEN-FANG-XIAO Decoction on a Persistent Asthmatic Mouse Model
title Proteomic Analysis Provides Insights Into the Therapeutic Effect of GU-BEN-FANG-XIAO Decoction on a Persistent Asthmatic Mouse Model
title_full Proteomic Analysis Provides Insights Into the Therapeutic Effect of GU-BEN-FANG-XIAO Decoction on a Persistent Asthmatic Mouse Model
title_fullStr Proteomic Analysis Provides Insights Into the Therapeutic Effect of GU-BEN-FANG-XIAO Decoction on a Persistent Asthmatic Mouse Model
title_full_unstemmed Proteomic Analysis Provides Insights Into the Therapeutic Effect of GU-BEN-FANG-XIAO Decoction on a Persistent Asthmatic Mouse Model
title_short Proteomic Analysis Provides Insights Into the Therapeutic Effect of GU-BEN-FANG-XIAO Decoction on a Persistent Asthmatic Mouse Model
title_sort proteomic analysis provides insights into the therapeutic effect of gu-ben-fang-xiao decoction on a persistent asthmatic mouse model
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6514195/
https://www.ncbi.nlm.nih.gov/pubmed/31133848
http://dx.doi.org/10.3389/fphar.2019.00441
work_keys_str_mv AT liuliwei proteomicanalysisprovidesinsightsintothetherapeuticeffectofgubenfangxiaodecoctiononapersistentasthmaticmousemodel
AT xingqiongqiong proteomicanalysisprovidesinsightsintothetherapeuticeffectofgubenfangxiaodecoctiononapersistentasthmaticmousemodel
AT zhaoxia proteomicanalysisprovidesinsightsintothetherapeuticeffectofgubenfangxiaodecoctiononapersistentasthmaticmousemodel
AT tanmin proteomicanalysisprovidesinsightsintothetherapeuticeffectofgubenfangxiaodecoctiononapersistentasthmaticmousemodel
AT luyuan proteomicanalysisprovidesinsightsintothetherapeuticeffectofgubenfangxiaodecoctiononapersistentasthmaticmousemodel
AT dongyingmei proteomicanalysisprovidesinsightsintothetherapeuticeffectofgubenfangxiaodecoctiononapersistentasthmaticmousemodel
AT daichen proteomicanalysisprovidesinsightsintothetherapeuticeffectofgubenfangxiaodecoctiononapersistentasthmaticmousemodel
AT zhangyang proteomicanalysisprovidesinsightsintothetherapeuticeffectofgubenfangxiaodecoctiononapersistentasthmaticmousemodel